« Return to News | Ethics/Regulatory

Harvard disciplines three psychiatrists under Sunshine Act

Wednesday, July 6, 2011 09:59 AM

Harvard Medical School and Massachusetts General Hospital have disciplined three faculty members in a conflict-of-interest case that became a prime exhibit in the debate over the federal Physician Payments Sunshine Act of 2010, according to the NPR Health Blog.

Drs. Joseph Biederman, Thomas Spencer and Timothy Wilens were accused of accepting more than $4.2 million from drug companies for psychiatric research and other activities between 2000 and 2007 without reporting the income to Harvard, MGH or the federal government.

Harvard and MGH are barring the three from accepting payments for "all paid industry-sponsor outside activities" for one year. After that, they'll have to seek approval before engaging in any "paid activities" and report to Harvard and the MGH on those activities for an additional two years.

The three will also undergo training on conflict-of-interest and will suffer "a delay of consideration for promotion or advancement."

"Our mistakes were honest ones," the doctors said in their letter. "We always believed that we were complying in good faith with institutional policies."

Industry payments to Biederman and his colleagues made headlines in 2008 when Sen. Charles E. Grassley (R-IA) accused them of understating, or failing to report at all, millions of dollars in support. Grassley detailed many discrepancies between what various drug companies said they paid the doctors and what the doctors reported to Harvard and MGH.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.